(Q34804885)

4 August 2017

1 reference

title

The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics (English)

1 reference

ORCID Public Data File 2021

4 August 2017

1 reference

1 reference

1 reference

author name string

Toutain PL

series ordinal

1

1 reference

PubMed ID

12204627

4 August 2017

del Castillo JR

series ordinal

2

1 reference

PubMed ID

12204627

4 August 2017

Bousquet-Mélou A

series ordinal

3

1 reference

4 August 2017

1 October 2002

1 reference

Research in Veterinary Science

4 August 2017

1 reference

4 August 2017

73

1 reference

4 August 2017

2

1 reference

4 August 2017

105-114

1 reference

Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Limitations of single point pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Sponsorship, authorship and accountability

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Challenges to antibiotic activity in tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Towards a common susceptibility testing method?

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Relevance of antibiotic tissue penetration in treating respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Rational dosing of antimicrobial drugs: animals versus humans

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Measuring the comparative efficacy of antibacterial agents for acute otitis media: The “Pollyanna phenomenon”

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

AUIC--the universal parameter within the constraint of a reasonable dosing interval

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Relationship between in vitro sensitivity of coliform pathogens in the udder and the outcome of treatment for clinical mastitis

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies

1 reference

https://api.crossref.org/works/10.1016%2FS0034-5288%2802%2900039-5

7 January 2021

10.1016/S0034-5288(02)00039-5

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12204627